4.6 Review

CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 21, Issue 1, Pages 41-48

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2009.11.009

Keywords

CCL2; CCR2; Tumorigenesis; Metastasis; Prostate cancer

Funding

  1. DOD [PC061231]
  2. NIH [P01 CA093900, P50 CA69568]
  3. American Cancer Society
  4. Cancer Center [P30 CA46592]
  5. Southwest Oncology Group [CA32102]
  6. Prostate Cancer Foundation

Ask authors/readers for more resources

CCL2 is a chemokine known to recruit monocytes and macrophages to sites of inflammation. A growing body of research suggests CCL2 is progressively overexpressed in tumor beds and may play a role in the clinical progression of solid tumors. Cancer cells derived from several solid tumor types demonstrate functional receptors for CCL2, suggesting this chemokine may achieve tumorigenicity through direct effects on malignant cells; however, a variety of normal host cells that co-exist with cancer in the tumor microenvironment also respond to CCL2. These cells include macrophages, osteoclasts, endothelial cells, T-lymphocytes, and myeloid-derived immune suppressor cells (MDSCs). CCL2 mediated interactions between normal and malignant cells in the tumor microenvironment and plays a multi-faceted role in tumor progression. (C) 2009 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available